Clinical Study

A Phase 3 Randomized, Multicenter, Multinational, Double-Blinded Study Comparing The Efficacy And Safety Of Repeated Biweekly Infusions Of Neogaa (Gz402666) And Alglucosidase Alfa In Treatment-Naïve Patients With Late Onset Pompe Disease

Posted Date: Oct 6, 2017

  • Investigator: Hani Kushlaf
  • Co-Investigator: Melissa Kahler
  • Specialties: Neurology, Neuromuscular Disorders
  • Type of Study: Drug

The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease), as well as pharmacokinetics (breakdown, use and removal from the body of the study drug (neoGAA) of the study drug (neoGAA) compared to Myozyme®/Lumizyme® (


To Be Considered For This Study, You Must Have Been Diagnosed With Late Onset Pompe Disease (Acid A Glucosidase (Gaa) Deficiency) And Have Never Received The Study Drug (Neogaa), Myozyme®/Lumizyme® Or Other Investigational Drug In A Clinical Study For Yo


Abnormal Emg, Myopathy, Pompe, Elevated Liver Enzymes, Enzyme Replacement Therapy

For More Information:

Alecia Corcoran
(513) 558-0039

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.